Shaping up to new realities in the NHS
As a more integrated and networked system of decision-making takes root across the NHS, Oli Hudson looks at the key strategic and organisational challenges pharmaceutical companies will need to address
Search Results for: Oli Hudson
Getting it right first time – pharma’s chance to shine?
As an influential new series of quality improvement reports illustrate how the NHS is shifting its focus to population health, Oli Hudson explores the opportunities for pharma
Are you ready to dive into a new era for medicines funding?
With crucial changes to funding models and new formulary arrangements emerging at system and place levels, Oli Hudson shares the latest intelligence on how the drug funding landscape will be affected by reforms, and how industry must adapt accordingly
Read More
(New) terms of engagement
With the pandemic and structural reforms taking their toll on the NHS workforce, Oli Hudson looks at how pharma can develop a sensitive and intelligent engagement approach that reflects the climate of change and uncertainty faced by clinical teams
Read More
Integration and innovation: reshaping the NHS
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes some of the most important reforms for health and social care for nearly ten years
Read More- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
- Study finds mechanical changes in tumour tissue offer new insights for cancer research
- Cambridge study finds AI more accurately assesses eye problems compared to doctors
- MIT researchers find circadian rhythms in liver function influence drugs’ effectiveness
- KCL study reveals particles in cows’ milk effective for oral delivery of RNA drugs
